(VIANEWS) - United Therapeutics Corporation (UTHR), Tetra Technologies (TTI), Telefonica Brasil, S.A. ADS (VIV) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. United Therapeutics Corporation (UTHR)
20.8% sales growth and 15.85% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $11.54.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 24.17. Meaning, the purchaser of the share is investing $24.17 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.85%.Growth Estimates Quarters
The company's growth estimates for the present quarter and the next is 13.7% and 56.6%, respectively.Volume
Today's last reported volume for United Therapeutics Corporation is 1008110 which is 170.13% above its average volume of 373190.
Moving Average
United Therapeutics Corporation's value is way higher than its 50-day moving average of $251.52 and way above its 200-day moving average of $219.37.Yearly Top and Bottom Value
United Therapeutics Corporation's stock is valued at $278.96 at 00:22 EST, below its 52-week high of $283.09 and way higher than its 52-week low of $158.38.
2. Tetra Technologies (TTI)
11.5% sales growth and 8.65% return on equity
TETRA Technologies Inc. and its subsidiaries operate as a diversified oil-and gas services company. Completion Fluids & Products and Water & Flowback Services are its two main segments. Clear brine fluids, chemicals, and other products are manufactured and sold by the Completion Fluids & Products division. They can be used in completion and well drilling operations throughout the United States as well as Europe, Asia and the Middle East. The segment sells both liquid and dried calcium chloride products. Water & Flowback Services provides services to water managers for oil and gas producers. The segment offers services such as frac flowback and production well testing. It also provides offshore cooling and related services for oil and gas operators in all of the major US and Mexican regions. The Woodlands is the headquarters of this company, which was founded in 1981.
Earnings per Share
Tetra Technologies' trailing twelve-month EPS is $0.08.
PE Ratio
Tetra Technologies' trailing 12 months earnings to price ratio is 42.5. The purchaser of the shares is therefore investing $42.5 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 8.65%.Sales Growth
Tetra Technologies has seen a 19.8% increase in sales for its current quarter, and an 11.5% rise for the next.
Volume
Today's last reported volume for Tetra Technologies is 650450 which is 44.31% below its average volume of 1168070.
Revenue Growth
Year-on-year quarterly revenue growth grew by 41.4%, now sitting on 518.91M for the twelve trailing months.
3. Telefonica Brasil, S.A. ADS (VIV)
7% sales growth and 8.03% return on equity
Telefônica Brasil S.A., together with its subsidiaries, provides mobile and fixed telecommunications services to residential and corporate customers in Brazil. Its fixed line services portfolio includes local, domestic long-distance, and international long-distance calls; and mobile portfolio comprises voice and broadband internet access through 3G, 4G, 4.5G, and 5G as well as mobile value-added services and wireless roaming services. The company also offers data services, including broadband and mobile data services. In addition, it provides pay TV services through direct to home satellite technology, IPTV, and cable, as well as pay-per-view and video on demand services; network services, such as rental of facilities; other services comprising internet access, private network connectivity, computer equipment leasing, extended service, caller identification, voice mail, cellular blocker, and others; wholesale services, including interconnection services to users of other network providers; and digital services, such as entertainment, cloud, and security and financial services. Further, the company offers multimedia communication services, which include audio, data, voice and other sounds, images, texts, and other information, as well as sells devices, such as smartphones, broadband USB modems, and other devices. Additionally, it provides telecommunications solutions and IT support to various industries, such as retail, manufacturing, services, financial institutions, government, etc. It markets and sells its solutions through own stores, dealers, retail and distribution channels, door-to-door sales, and outbound tele sales. The company was formerly known as Telecomunicações de São Paulo S.A. - TELESP and changed its name to Telefônica Brasil S.A. in October 2011. The company was incorporated in 1998 and is headquartered in São Paulo, Brazil.
Earnings Per Share
As for profitability, Telefonica Brasil, S.A. ADS has a trailing twelve months EPS of $0.52.
PE Ratio
Telefonica Brasil, S.A. ADS has a trailing twelve months price to earnings ratio of 13.76. Meaning, the purchaser of the share is investing $13.76 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.03%.Revenue growth
The year-over-year revenue growth was 10.6%. It now stands at 46.88B in the 12 trailing months.
4. Insulet (PODD)
6.8% sales growth and 7.85% return on equity
Insulet Corporation designs, produces, and markets insulin delivery systems to people suffering from insulin-dependent diabetes. The Omnipod System is a disposable, self-adhesive, tubeless Omnipod device. It can be worn on the body up to 3 days. It sells products through independent distributors, pharmacy channels and directly within the United States, Canada and Europe. Insulet Corporation was founded in 2000. It is located in Acton in Massachusetts.
Earnings per Share
Insulet's trailing 12 month EPS is $0.1.
PE Ratio
Insulet's trailing 12 months earnings to price ratio is 2921.6 The purchaser of the shares is investing $2921.6 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 7.85%.